Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Combined Radiotherapy and Sorafenib in Patients With Hepatoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01319942
Recruitment Status : Unknown
Verified March 2011 by China Medical University Hospital.
Recruitment status was:  Recruiting
First Posted : March 22, 2011
Last Update Posted : March 22, 2011
Sponsor:
Information provided by:
China Medical University Hospital

Tracking Information
First Submitted Date July 20, 2010
First Posted Date March 22, 2011
Last Update Posted Date March 22, 2011
Study Start Date June 2010
Estimated Primary Completion Date June 2012   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: March 21, 2011)
Response rate [ Time Frame: 1-month and 6-month response rate ]
  1. Response rate at 1-month and 6-month after radiotherapy.
  2. Toxicities profile of combinede treatment
Original Primary Outcome Measures Same as current
Change History No Changes Posted
Current Secondary Outcome Measures
 (submitted: March 21, 2011)
Time-to radiological progression interval [ Time Frame: 2-years ]
  1. Time-to radiological progression interval
  2. 2-year overall survival
  3. 2-year progression-free survival
  4. Quality of life
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Combined Radiotherapy and Sorafenib in Patients With Hepatoma
Official Title Combined Radiotherapy and Sorafenib in Patients With Hepatoma
Brief Summary This study aims to test the efficacy of combined radiotherapy and sorafenib in patients with locally advanced hepatocellular carcinoma.
Detailed Description

Hepatocellular carcinoma (HCC) is a common cause of cancer mortality in Asia. Most patients present with intermediate or advanced disease. Percutaneous ethanol injection, radiofrequency ablation, and transcatheter arterial chemoembolization (TACE) are not considered as a curative treatment and have achieved very limited success in eradicating large HCC. With the development of new radiotherapy (RT) technique, RT can be more safely given to patients with larger tumor burden. Thus, TACE combined with RT has been suggested for treating large HCC. Based on the results of these studies, RT could achieve a tumor response rate of 50 % to 70 %. However, it has not been definitively shown to prolong the overall or disease-free survival due to lack of a phase III clinical trial. In contrast, a retrospective clinical investigation with molecular study suggests that sublethal dose of RT promoted HCC growth outside RT field.

Two phase III trials were shown to be efficacious and well-tolerated in patients with advanced HCC. Median overall survival was significantly 2 to 3 months longer in the sorafenib group than that in the placebo. It is interesting to recognize the combined therapeutic effect of RT with sorafenib. Based on several preclinical experiments, tumor angiogenesis inhibitors seem to be synergistic with irradiation when using before RT, concurrently with RT, or after RT. Thus, we design a single-arm phase II clinical trial to investigate the efficacy of combined RT with sorafenib.

The eligibility criteria are patients with unresectable HCC; good performance status; no prior radiotherapy for the liver; clinical measurable tumor; good liver function and good compliance. After entering this study, the testee will receive RT to hepatic tumor with concurrently sorafenib with a dose of 400 mg twice daily. Hepatic RT will be performed with a daily fraction size of 2.0 to 2.5 Gy to a total dose of 46 Gy to 60 Gy. After RT, maintenance sorafenib with a dose of 400 mg twice daily will be ongoing. Sorafenib will be continued until the occurrence of clinical or radiologic progression, or the occurrence of either unacceptable adverse events or death. Minimum maintenance duration of 6 months is recommended, but not mandatory. The primary end points are response rate and toxicities profile. The secondary endpoints are time to radiological progression interval (TRPI), overall survival, and quality of life assessment.

Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population 45 patients withunresectable hepatoma
Condition Hepatocellular Carcinoma
Intervention Other: Radiotherapy combined with sorafenib
Radiotherapy: 46 Gy to 60 Gy prescribed to involved hepatic tumor Sorafenib: 2 tablet of sorafenib (200mg) twice daily (totally 800mg per day)
Other Name: Radiotherapy with sorafenib
Study Groups/Cohorts Unresectable hepatoma
Unresectable hepatoma, unsuitable for transarterial embolization or local failure after transarterial embolization
Intervention: Other: Radiotherapy combined with sorafenib
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Unknown status
Estimated Enrollment
 (submitted: March 21, 2011)
45
Original Estimated Enrollment Same as current
Estimated Study Completion Date June 2013
Estimated Primary Completion Date June 2012   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  1. Patients with unresectable hepatoma with transarterial embolization (TAE) failure or who are not suitable for TAE.
  2. Age: 20 ~ 69 years.
  3. ECOG 0 or 1.
  4. Life expectancy of at least 12 weeks.
  5. Child-Pugh A or B (preferentially score ≦ 7).
  6. Cancer of the Liver Italian Program (CLIP) score ≦ 3.
  7. Pretreatment liver function test and renal function test:

    • Total bilirubin < 1.5 times the upper limit of normal (ULN)≦ 3.0(ULN)in patients treated by biliary drainage for obstructive jaundice.
    • GOP/GPT ≦ 5 X of upper limit of normal range.
    • Alkaline phosphatase ≦ 4X of upper limit of normal range.
    • Prothrombin time/partial prothrombin time < 1.5 X of ULN.
    • Serum Creatinine ≦ 1.0 x ULN.
  8. Pretreatment blood count:

    • Hemoglobulin ≧ 9 g/dl.
    • Absolute neutrophil count ≧ 1500/mm3.
    • Platelet count ≧ 100,000/mm3.
  9. Subjects with at least one uni-dimensional or bi-dimensional measurable lesion. Lesion must be measured by CT scan or MRI.
  10. Patients must fully recover from prior therapy that given > 4 weeks before enrolment.11. Signed informed consent must be obtained prior to any study related procedures.

Exclusion Criteria:

  1. Child-Pugh C
  2. CLIP score ≧ 4
  3. Patients with evidence of extrahepatic or metastatic disease
  4. Patients with evidence of massive ascites
  5. Patients receiving previous irradiation to liver
  6. Patients with previous use of Thalidomide less than 6 months from entering of the study
  7. History of cardiac disease: congestive heart failure >NYHA class 2; active CAD (MI more than 6 mo prior to study entry is allowed); cardiac arrythmias requiring anti-arrythmic therapy (beta blockers or digoxin are permitted)
  8. Active clinically serious infections ( > grade 2 CTC version 2)
  9. Patients undergoing renal dialysis
  10. Patients with evidence or history of bleeding diathesis
  11. Prior treatment with EGFR TKIs or VEGFR TKIs
  12. Hypertension uncontrolled by medical therapy
  13. Symptomatic metastatic brain or meningeal tumors unless the patient is > 6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry. Also the patient must not be undergoing acute steroid therapy or taper.
  14. Chemotherapy or immunotherapy or other systemic anti-cancer therapy within 4 weeks (6 weeks for nitrosoureas, mitomycin and suramin)
  15. Major surgery within 4 weeks of start of study
  16. Concomitant treatment with strong CYP3A4 inducers or inhibitors
  17. Investigational drug therapy outside of this trial during or within 4 weeks of study entry
  18. Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment.
  19. Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation, including the 30 days period after last study drug dosing.
  20. Pregnant or breast-feeding patients
  21. Known or suspected allergy to the investigational agent or any agent given in association with this trial
  22. Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors [Ta, Tis & T1] or any cancer curatively treated > 3 years prior to study entry
  23. Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study
  24. Patients with seizure disorder requiring medication
  25. History of organ allograft
  26. Use of biologic response modifiers, such as G-CSF, within 3 week of study entry
  27. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
  28. Autologous bone marrow transplant or stem cell rescue within 4 months of study
  29. Patients unable to swallow oral medications
Sex/Gender
Sexes Eligible for Study: All
Ages 20 Years to 69 Years   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Taiwan
Removed Location Countries  
 
Administrative Information
NCT Number NCT01319942
Other Study ID Numbers RT-sorafenib
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Shang-Wen Chen, China Medical University Hospital
Study Sponsor China Medical University Hospital
Collaborators Not Provided
Investigators
Principal Investigator: Shang-Wen Chen, MD Department of Radiation Oncology, China Medical University Hospital
PRS Account China Medical University Hospital
Verification Date March 2011